Allergan Makes New Appointments to Finance Leadership Team
|
DUBLIN, Nov. 26, 2018 /PRNewswire/ -- Allergan, plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Daphne Karydas will take on the new role of Senior Vice President Corporate Financial Planning & Analysis and Strategy, and Manisha Narasimhan, PhD, will join the Company as Vice President of Investor Relations and Strategic Initiatives, effective December 10, 2018.
In her new role, Ms. Karydas will continue to work with the Executive Leadership Team to develop and execute the Company's long-term financial and business strategy. Dr. Narasimhan, who joins Allergan from Regeneron Pharmaceuticals, Inc., will lead the Company's engagement with the investment community. Both roles will report to Matt Walsh, Executive Vice President and Chief Financial Officer. "The changes we are announcing today will enable us to further deepen our focus on the corporate strategic and financial planning functions to realize Allergan's long-term growth potential, while continuing to develop and steward the strong relationships we have established across the financial community," said Walsh. Dr. Narasimhan joins Allergan from Regeneron, where she led the Investor Relations function. She has extensive industry experience in the biopharmaceutical sector and well-established relationships within the investment community. Previously, she was an equity research analyst at Canaccord Genuity and Piper Jaffray and has also served as a strategy consultant at Campbell Alliance. Dr. Narasimhan holds a B.Sc. from University of Madras in India and a PhD in Microbiology from New York University. "We always look to position ourselves to deliver the highest value to patients, customers and shareholders," said Brent Saunders, Chairman and Chief Executive Officer of Allergan. "A strong financial and strategic planning capability is essential to Allergan's growth, and Daphne's leadership in this area will help take us to the next level. With Manisha's impressive mix of financial and biopharma industry experience, we will continue to build on the solid foundation Daphne set in Investor Relations." Ms. Karydas recently served as Senior Vice President Global Investor Relations and Strategy. Before that time, she was a leading institutional investor and financial analyst in the biopharmaceutical sector, joining from J.P. Morgan Asset Management. Ms. Karydas holds a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. About Allergan plc Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories. Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry. Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right. With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day. For more information, visit Allergan's website at www.Allergan.com. Forward-Looking Statement Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. CONTACTS: Allergan: Karina Calzadilla Media: Lisa Brown
SOURCE Allergan plc |
Company Codes: NYSE:AGN |
View original content to download multimedia: